Past, Recent Progresses and Future Perspectives of Nanotechnology Applied to Antifungal Agents

Author(s): Luis Roque, Jesus Molpeceres, Claudia Reis, Patrícia Rijo, Catarina Pinto Reis*

Journal Name: Current Drug Metabolism

Volume 18 , Issue 4 , 2017

Become EABM
Become Reviewer
Call for Editor


Candida species remain a significant cause of nosocomial bloodstream infections, associated with prolonged hospital stay in the ICU and high healthcare cost. The incidence of Candida is very high in certain risk groups of patients (AIDS, diabetes, cancer, etc.). Recent developments of nanotechnology have strongly contributed to the design of new multifunctional drug carriers that improve drug bioavailability through a controlled and prolonged release profile or even through a more specific targeted delivery of the antifungal agent. Those types of systems have strongly increased with a progressive generation of new structures, permitting the conjunction of new materials, biomolecules, physical and chemical techniques, for better outcomes. Nanotechnology shows expanded possibilities within the medical field and in the case of the yeast infections it may overcome several issues related with the fungal proliferation or higher inhibition of the pathogen causing the infection. This review covers a period of the most representative research of Candidiasis since 1993 to the present.

Keywords: Fungal infections, candidiasis, encapsulation, antifungal agents, nanoparticles, mucoadhesion.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 01 February, 2017
Page: [280 - 290]
Pages: 11
DOI: 10.2174/1389200218666170201152000
Price: $65

Article Metrics

PDF: 39
PRC: 1